STAB1 and atherosclerosis: The results of this study show that inhibiting either Stab1 or Stab2 does not appear to pose a strongly increased risk of exacerbating fibrotic or inflammatory skin conditions, which suggests that an anti‐Stabilin targeted therapy in atherosclerosis or cancer therapy might not lead to adverse effects in inflammatory or fibrotic skin conditions.